바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

738누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodystaleEli LillyPhase 2

SCCHN (Cetuximab, Cetuximab (SCCHN))

Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of th… · Incurable Metastatic Colorectal Carcinom

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

SCCHN (Cetuximab, Cetuximab (SCCHN))

Cetuximab and FOLFIRI (Cetuximab and FOLFIRI)

mFOLFOX-6 + cetuximab until disease progression or early withdrawal. (mFOLFOX-6 + cetuximab until disease progression or early withdrawal.)

8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal. (8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.)

Dose escalation cetuximab (Dose escalation cetuximab)

Standard dose cetuximab (Standard dose cetuximab)

Cetuximab and FOLFOX (Cetuximab and FOLFOX)

standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab (standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab)

irinotecan, cetuximab, envafolimab (irinotecan, cetuximab, envafolimab)

Docetaxel, Cisplatin, 5-FU and Cetuximab (Docetaxel, Cisplatin, 5-FU and Cetuximab)

Cetuximab β；Fruquintinib； (Cetuximab β；Fruquintinib；)

Cetuximab β；Fruquintinib；anti-PD1 antibody； (Cetuximab β；Fruquintinib；anti-PD1 antibody；)

Irinotecan/Cetuximab (Irinotecan/Cetuximab)

Capecitabine (Xelodaâ, Capecitabine, Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®))

Dose escalation of cetuximab (Dose escalation of cetuximab)

Standard first line treatment with cetuximab + Folfiri (Standard first line treatment with cetuximab + Folfiri)

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

TAK-981 + Avelumab (TAK-981 + Avelumab)

Colorectal cancer: Tunlametinib + cetuximab β (Colorectal cancer: Tunlametinib + cetuximab β)

Pancreatic cancer: Tunlametinib + cetuximab β (Pancreatic cancer: Tunlametinib + cetuximab β)

Pancreatic cancer: Tunlametinib +Nimotuzumab (Pancreatic cancer: Tunlametinib +Nimotuzumab)

Capecitabine and Cetuximab (Capecitabine and Cetuximab)

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

administered with & without Cetuximab (Irinotecan, Irinotecan (administered with & without Cetuximab))

nivolumab (Opdivo, Nivolumab + Paclitaxel)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

SCCHN (Cetuximab, Cetuximab (SCCHN))

Cetuximab and FOLFIRI (Cetuximab and FOLFIRI)

mFOLFOX-6 + cetuximab until disease progression or early withdrawal. (mFOLFOX-6 + cetuximab until disease progression or early withdrawal.)

8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal. (8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.)

Dose escalation cetuximab (Dose escalation cetuximab)

Standard dose cetuximab (Standard dose cetuximab)

Cetuximab and FOLFOX (Cetuximab and FOLFOX)

standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab (standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab)

irinotecan, cetuximab, envafolimab (irinotecan, cetuximab, envafolimab)

Docetaxel, Cisplatin, 5-FU and Cetuximab (Docetaxel, Cisplatin, 5-FU and Cetuximab)

Cetuximab β；Fruquintinib； (Cetuximab β；Fruquintinib；)

Cetuximab β；Fruquintinib；anti-PD1 antibody； (Cetuximab β；Fruquintinib；anti-PD1 antibody；)

Irinotecan/Cetuximab (Irinotecan/Cetuximab)

Capecitabine (Xelodaâ, Capecitabine, Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®))

Dose escalation of cetuximab (Dose escalation of cetuximab)

Standard first line treatment with cetuximab + Folfiri (Standard first line treatment with cetuximab + Folfiri)

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

TAK-981 + Avelumab (TAK-981 + Avelumab)

Colorectal cancer: Tunlametinib + cetuximab β (Colorectal cancer: Tunlametinib + cetuximab β)

Pancreatic cancer: Tunlametinib + cetuximab β (Pancreatic cancer: Tunlametinib + cetuximab β)

Pancreatic cancer: Tunlametinib +Nimotuzumab (Pancreatic cancer: Tunlametinib +Nimotuzumab)

Capecitabine and Cetuximab (Capecitabine and Cetuximab)

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

administered with & without Cetuximab (Irinotecan, Irinotecan (administered with & without Cetuximab))

nivolumab (Opdivo, Nivolumab + Paclitaxel)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

SCCHN (Cetuximab, Cetuximab (SCCHN))

Cetuximab and FOLFIRI (Cetuximab and FOLFIRI)

mFOLFOX-6 + cetuximab until disease progression or early withdrawal. (mFOLFOX-6 + cetuximab until disease progression or early withdrawal.)

8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal. (8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.)

Dose escalation cetuximab (Dose escalation cetuximab)

Standard dose cetuximab (Standard dose cetuximab)

Cetuximab and FOLFOX (Cetuximab and FOLFOX)

standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab (standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab)

irinotecan, cetuximab, envafolimab (irinotecan, cetuximab, envafolimab)

Docetaxel, Cisplatin, 5-FU and Cetuximab (Docetaxel, Cisplatin, 5-FU and Cetuximab)

Cetuximab β；Fruquintinib； (Cetuximab β；Fruquintinib；)

Cetuximab β；Fruquintinib；anti-PD1 antibody； (Cetuximab β；Fruquintinib；anti-PD1 antibody；)

Irinotecan/Cetuximab (Irinotecan/Cetuximab)

Capecitabine (Xelodaâ, Capecitabine, Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®))

Dose escalation of cetuximab (Dose escalation of cetuximab)

Standard first line treatment with cetuximab + Folfiri (Standard first line treatment with cetuximab + Folfiri)